AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - March 29, 2023) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
Lead Plaintiff Deadline: May 12, 2023
No obligation or cost to you.

Learn more about your recoverable losses in AMGN:
https://www.kleinstocklaw.com/pslra-1/amgen-class-action-submission-form?id=37866&from=5

Amgen Inc. NEWS - AMGN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Amgen Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the U.S. government claimed Amgen owed more than $3 billion in back taxes for tax years 2010, 2011, and 2012; (b) the U.S. government claimed Amgen owed more than $5 billion in back taxes for tax years 2013, 2014, and 2015; (c) the U.S. government would likely claim Amgen owed materially more to the U.S. government than investors had been led to believe for subsequent tax years for which the Company had used the same profit allocation treatment between its U.S. and Puerto Rico operations; (d) Amgen had not taken sufficient accruals to account for its outstanding tax liabilities; (e) Amgen had failed to comply with Accounting Standards Codification Topic 450 and other rules and regulations regarding the preparation of its periodic filings with the U.S. Securities and Exchange Commission; and (f) Amgen's refusal to pay taxes claimed by the U.S. government exposed the Company to a substantial risk of severe financial penalties imposed by the Internal Revenue Service.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Amgen you have until May 12, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Amgen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the AMGN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/160455